Plant allergens are proteins found in various parts of plants that can elicit allergic reactions in susceptible individuals. Common sources of plant allergens include pollen, fruits, vegetables, nuts, and seeds. Allergic responses to plant allergens can manifest as respiratory symptoms (hay fever), skin reactions, or gastrointestinal issues. Pollen allergens, prevalent during specific seasons, contribute to hay fever or allergic rhinitis. Cross-reactivity between certain pollens and proteins in fruits or vegetables can lead to oral allergy syndrome (OAS), causing itching or swelling in the mouth and throat. Prominent plant allergens include proteins like profilins, lipid transfer proteins (LTPs), and pathogenesis-related proteins. Sensitization to these allergens can occur through inhalation, ingestion, or skin contact. Management of plant allergies involves allergen avoidance, symptomatic relief with antihistamines or corticosteroids, and in severe cases, allergen immunotherapy. Ongoing research focuses on understanding the molecular basis of plant allergies, improving diagnostic methods, and exploring potential therapeutic interventions to alleviate symptoms and enhance the quality of life for individuals affected by plant allergens.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States